-
公开(公告)号：US11014927B2
公开(公告)日：2021-05-25
申请号：US16496279
申请日：2018-03-20
Applicant: FORMA Therapeutics, Inc.
Inventor： Anna Ericsson , Neal Green , Gary Gustafson , Bingsong Han , David R. Lancia, Jr. , Lorna Mitchell , David Richard , Tatiana Shelekhin , Chase C. Smith , Zhongguo Wang , Xiaozhang Zheng
IPC: C07D487/04 , C07D519/00 , A61P7/00 , A61K9/00 , A61K31/407
Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
-
52.发明授权公开(公告)号：US10807976B2
公开(公告)日：2020-10-20
申请号：US16517866
申请日：2019-07-22
Applicant: FORMA Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, Jr. , Justin Andrew Caravella , Wei Lu
IPC: C07D417/12 , C07D417/14 , C07D471/04 , A61P35/00
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
-
53.发明申请公开(公告)号：US20200223822A1
公开(公告)日：2020-07-16
申请号：US16712951
申请日：2019-12-12
Applicant: FORMA Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , A61P35/00 , C07D471/04 , C07D401/14
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
-
公开(公告)号：US20200085798A1
公开(公告)日：2020-03-19
申请号：US16576360
申请日：2019-09-19
Applicant: FORMA Therapeutics, Inc.
Inventor： Anna Ericsson , Neal Green , Gary Gustafson , David R. Lancia, JR. , Gary Marshall , Lorna Mitchell , David Richard , Zhongguo Wang
IPC: A61K31/436
Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
-
55.发明申请公开(公告)号：US20200010464A1
公开(公告)日：2020-01-09
申请号：US16517866
申请日：2019-07-22
Applicant: FORMA Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D417/12 , C07D417/14 , C07D471/04 , A61P35/00
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
-
Patent Agency Ranking
公开(公告)号：US20190263779A1
公开(公告)日：2019-08-29
申请号：US16290328
申请日：2019-03-01
Applicant: FORMA Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D403/12 , C07D409/14 , C07D471/04 , C07D405/14 , C07D417/14 , C07D401/14 , C07D413/14
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
-
57.发明申请公开(公告)号：US20180312487A1
公开(公告)日：2018-11-01
申请号：US15964844
申请日：2018-04-27
Applicant: FORMA Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D471/04 , C07D401/14 , A61K31/47
CPC classification number: C07D401/12 , A61K31/47 , A61P35/00 , C07D401/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
-
公开(公告)号：US09815817B2
公开(公告)日：2017-11-14
申请号：US14858165
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R Bruce Diebold , Susan Ashwell , David R. Lancia, Jr. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/14 , C07D405/14 , C07D413/14 , C07D401/12 , C07D409/14 , C07D417/14 , C07D471/04 , A61K31/506 , C07D403/12
CPC classification number: C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
-
59.发明申请QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS 有权喹诺酮五元杂环化合物作为突变型脱氢酶抑制剂公开(公告)号：US20160311818A1
公开(公告)日：2016-10-27
申请号：US14858153
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, Jr. , Justin Andrew Caravella , Wei Lu
IPC: C07D471/04 , C07D417/14 , C07D417/12
CPC classification number: C07D417/12 , A61P35/00 , C07D417/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
Abstract translation: 其中描述了Y1，X1，X2，Y2，W1，W2，W3和R1-R5。
-
60.发明申请PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS 有权吡啶基喹啉酮衍生物作为突变型脱氢酶抑制剂公开(公告)号：US20160083367A1
公开(公告)日：2016-03-24
申请号：US14858170
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D401/14 , C07D417/14 , C07D413/14
CPC classification number: C07D401/12 , A61K31/4704 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
Abstract translation: 本发明涉及用于治疗细胞增殖障碍和癌症的具有新形态活性的突变异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，其具有下式：其中A，B，U，V，Z，W1，W2，W3 ，和R1-R6。
-
-
-
-
-
-
-
-
-
Search Results
62
records
(took 0.045 seconds)
